替吉奥、顺铂联合多西他赛协同治疗宫颈癌的临床效果

Clinical effect of Tigapine and Cisplatin combined with Docetaxel in the treatment of cervical cancer

目的观察替吉奥、顺铂联合多西他赛协同治疗宫颈癌的临床效果,初步探讨其可能的起效机制。方法选择2017年6月~2019年1月湖北省武汉市协和医院收治的宫颈癌患者112例为研究对象,按照随机数字表法分为对照组和观察组,每组56例。对照组给予替吉奥联合顺铂治疗,观察组在对照组基础上加用多西他赛,比较两组的临床疗效,血清肿瘤标志物、Th1/Th2细胞因子含量、免疫功能水平变化,记录用药过程的不良反应。结果观察组疾病控制率、客观缓解率高于对照组,差异有统计学意义(P<0.05)。治疗后两组癌胚抗原、糖类抗原19-9(CA19-9)、CA125、鳞状上皮细胞癌抗原水平低于治疗前,且观察组低于对照组,差异均有统计学意义(均P<0.05)。治疗后观察组γ干扰素(IFN-γ)、肿瘤坏死因子-α(TNF-α)、白细胞介素-2(IL-2)水平高于治疗前,IL-4、IL-6、IL-10水平低于治疗前;观察组IFN-γ、TNF-α、IL-2水平高于对照组,IL-4、IL-6、IL-10水平低于对照组,差异均有统计学意义(均P<0.05)。两组治疗过程中不良反应发生率比较,差异有统计学意义(P<0.05)。结论多西他赛、替吉奥联合顺铂治疗宫颈癌的临床效果确切,可降低血清肿瘤标志物水平,纠正Th1/Th2细胞免疫失衡状态,且减少不良反应,值得进行临床推广。

Objective To observe the clinical effect of Tigapine,Cisplatin and Docetaxel in the treatment of cervical cancer and to explore the possible mechanism of action.Methods From June 2017 to January 2019,112 cases with cervical cancer who admitted to Wuhan Union Hospital of Hubei Province were selected.According to random number table method,they were divided into control group and observation group,with 56 cases in each group.Control group was treated with Tigapine combined with Cisplatin and observation group was treated with Docetaxel on the basis of control group.The clinical efficacy of the two groups,and changes in serum tumor markers,Th1/Th2 cytokine content and immune function level was compared the adverse reactions during medication was recorded.Results The disease control rate and the objective remission rate of observation group were higher than those of control group,and the difference was statistically significant(P<0.05).After treatment,the levels of carcino-embryonic antigen,carbohydrate antigen 19-9(CA19-9),CA125 and squamous cell carcinoma antigen in two groups were lower than those before treatment,and observation group was lower than control group,and the differences were statistically significant(all P<0.05).After treatment,the levels ofγinterferon(IFN-γ),tumor necrosis factor-α(TNF-α)and interleukin-2(IL-2)in observation group were higher than those before treatment,and the levels of IL-4,IL-6 and IL-10 were lower than those before treatment;and the levels of IFN-γ,TNF-αand IL-2 in observation group were higher than those in control group,and the levels of IL-4,IL-6,and IL-10 in observation group were lower than those in control group,with statistically significant differences(all P<0.05).The incidence of adverse reactions during treatment in two groups was statistically significant(P<0.05).Conclusion The clinical effect of Docetaxel and Tigapine combined with Cisplatin in the treatment of advanced cervical cancer is definite,which is conducive to reducing the level of serum tumor markers,correcting the immune imbalance of Th1/Th2 cells and reducing adverse reactions,which is worthy of clinical promotion.